Biodesix, Inc. Common Stock
BDSXBiodesix, Inc. is a molecular diagnostics company specializing in blood-based tests for lung disease, including lung cancer and infectious diseases. The company develops and commercializes liquid biopsy tests to aid in early detection, diagnosis, and treatment monitoring, leveraging advanced proteomic and genomic technologies to improve patient outcomes.
Company News
Biodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will participate in three upcoming investor conferences in May and June 2026, including Craig-Hallum, William Blair Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution. The company will hold 1x1 meetings and present at select events, with presentations available for web...
Biodesix, Inc. (Nasdaq: BDSX) announced it will release first quarter 2026 financial results on May 4, 2026, after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
Biodesix, Inc. announced preliminary Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 2025. Management will participate in investor conferences in March 2026.
Biodesix reported estimated Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 and plans to present clinical utility data for its Nodify Lung tests at upcoming scientific meetings.
Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.
